Prepare yourselves, science fans, because the flu shot just leveled up. The FDA recently greenlit mFLUSIVA, Moderna's mRNA flu vaccine, for anyone 50 and over. That's right, the same tech that helped us tackle COVID is now coming for the flu. And honestly, it's about time.
Every year, the flu plays a surprisingly brutal game of whack-a-mole, claiming tens of thousands of lives, with the vast majority being our elders. So, a new tool in the arsenal? We'll take it.
The Old Way vs. The New Script
For the last 80 years, making a flu vaccine has been a bit like a high-stakes guessing game played with chicken eggs. Scientists had to predict which flu strain would be dominant six months in advance, growing viruses in eggs and hoping for the best. If the virus decided to mutate mid-season, well, tough luck. It's like ordering a pizza in January based on what you think you'll crave in September.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThen there were the protein-based vaccines, a bit faster but pricier. Now, mRNA steps onto the stage.
Instead of growing actual virus, mRNA vaccines deliver a tiny genetic instruction manual to your cells. Your cells read the script, produce a harmless piece of the flu virus, and your immune system learns to recognize and fight it. The best part? This script can be rewritten at warp speed. Got a new flu strain popping up? Update the script, press print. As Johns Hopkins professor Anna Durbin points out, this agility is a game-changer for fast-evolving viruses like flu and COVID.
Fast-Tracked for Your Safety
The FDA's committee of scientists took a good, hard look at mFLUSIVA's data. Their verdict: benefits outweigh the risks for the 50-plus crowd. Clinical trials showed it was about 26.6% more effective at preventing lab-confirmed flu than traditional vaccines and sparked a stronger immune response in those 65 and older. Serious side effects? Rare, and similar to what you'd see with a standard flu shot. This fast-tracked approval for a high-risk group makes a lot of sense.
With around 70,000 people already part of the safety trials, and the familiar mRNA platform from the COVID vaccines, Durbin expects its real-world safety to be solid. It's the same delivery system, just a different target.
What's Next for Your Arm?
So, will you be able to waltz into your pharmacy and demand the new mRNA shot this fall? That's still a bit up in the air. Availability and Moderna's pricing plans are under wraps. But FDA approval usually means insurance coverage, which is a good start.
Traditional flu shots aren't going anywhere, so you'll still have options. Durbin speculates that if the mRNA version is pricier, you might need to specifically ask for it. If the cost is comparable, it could just be another choice presented by your pharmacist.
This isn't just about flu, though. Durbin sees mRNA as the future of vaccines. Regulators in the EU, Canada, and Australia are also reviewing mFLUSIVA, and the EU has even approved a combined mRNA COVID-flu shot from Moderna. The infrastructure built during the pandemic means the US is now primed to quickly churn out adaptable mRNA vaccines.
While we wait for approval for younger folks (which requires more trials), this flu season will be a fascinating test case. If mFLUSIVA proves significantly more effective without any unexpected safety hiccups, it could become the new gold standard, much like Shingrix replaced Zostavax for shingles. The only potential snag? Public perception of mRNA technology, which, let's be honest, has had its fair share of drama. But a more effective flu shot that adapts on the fly? That's a story worth watching.
